Labor Market Pulse · Life Sciences · October 2026
Life Sciences Labor Market Report: Kennewick-Richland-Pasco, WA MSA — October 2026
Tri-Cities talent tightens as CRA and regulatory pay diverge sharply.
Tri-Cities unemployment fell to a multi-year low of 3.5% while local CRA advertised pay dropped to $68,456 against a national median of $90,065, even as Regulatory Affairs pay climbed to $125,173 locally.
Free archive edition. Published by WageScape as sent to subscribers; data as of October 2026.
Key indicators
- Tri-Cities unemployment rate: 3.5% — vs 4.8% WA, 4.2% national — multi-year local low
- CRA pay gap vs national median: -24% — $68,456 metro vs $90,065 national median
- Biopharma national quit rate: 1.9% — Low churn limits available experienced candidates
- WA statewide job loss, Sept 2026: -15,400 jobs — Even as unemployment fell to 4.8% statewide
Key takeaways
CRA pay gap versus national median may signal a quiet CRO shift.
Metro CRA advertised pay dropped significantly to $68,456 while the national median climbed to $90,065 — a roughly 24% gap that is unusual for a credential-driven, candidate-constrained role nationally. Worth testing whether local employers are structurally underpricing CRA talent or increasingly routing clinical monitoring work to CDMOs and CROs instead of building internal headcount.
Regulatory affairs compensation is pulling away from national trend.
Metro Regulatory Affairs Specialist pay rose moderately to $125,173 even as the national median slipped to $103,780, a reversal that is consistent with EUDAMED and EU AI Act compliance demands pulling regulatory talent into a smaller, more expensive pool. Compensation strategy for this role should be benchmarked against local scarcity, which better reflects current conditions than national softening does.
Sub-4% local unemployment tightens the build-versus-outsource calculus.
Tri-Cities unemployment at 3.5% sits more than a point below the national rate, and Washington's life sciences job growth has outpaced three prior recessions as a sector buffer. Internal hiring timelines for specialized R&D and quality roles should assume longer fill cycles than state or national averages imply, strengthening the case for CDMO partnerships on non-core manufacturing work.
Biostatistician pay decline bears watching against thin local supply.
Metro Biostatistician advertised pay fell significantly to $136,567 while the national median held flat near $131,958, an unusual pattern in a role tied to clinical trial throughput. A sustained local decline could reflect a smaller applicant pool resetting advertised ranges downward, a dynamic that would understate true scarcity.
Median advertised pay by role — Kennewick-Richland-Pasco, WA MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $83,387 | $129,815 | $150,711 | Stable | $130,339 |
| Clinical Research Associate | $65,707 | $68,456 | $78,457 | Significant decline | $90,065 |
| Lab Technician * | $46,930 | $57,200 | $67,234 | Stable | $47,840 |
| Regulatory Affairs Specialist | $118,815 | $125,173 | $125,174 | Moderate increase | $103,780 |
| Clinical Data Manager * | $97,353 | $120,009 | $130,457 | Stable | $123,653 |
| Biostatistician * | $110,345 | $136,567 | $158,319 | Significant decline | $131,958 |
| Validation Engineer * | $93,560 | $113,771 | $124,081 | Stable | $106,478 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Tri-Cities unemployment fell to 3.5% in September — a multi-year low and well below both the state's 4.8% and the national 4.2% rate — even as Washington's statewide labor market shed 15,400 jobs, signaling that local labor supply is tightening independent of broader state softness. Regional healthcare and manufacturing expansion continues to absorb workers while retail and office activity slows, concentrating competitive pressure on employers who need credentialed scientific, clinical, and manufacturing talent in a market with little slack left to draw from.
What it means
Sub-4% local unemployment combined with a national biopharma quit rate of 1.9% means Life Sci employers in this metro are competing for a pool of specialists who are largely not looking, raising the cost and timeline of filling regulatory, clinical operations, and biomanufacturing roles sourced through deliberate headcount planning. Diverging local pay signals — Regulatory Affairs Specialist up moderately to $125,173 while Clinical Research Associate pay fell sharply to $68,456, trailing the national median of $90,065 by nearly $22,000 — suggest the metro's CRA talent pool is either thinning or being valued inconsistently against national standards, a gap worth testing against actual fill times before assuming it reflects a stable market rate. Organizations should evaluate whether CRA roles priced at metro norms are drawing qualified candidates or quietly pushing clinical operations work toward CRO partners by default.
Looking ahead
Early indicator: Watch whether the metro's CRA pay gap versus the national median narrows or widens over the next two reporting cycles — a continued widening would support routing more clinical monitoring work through CRO partners instead of expanding internal headcount.
Emerging pressure point: Washington's EU-linked regulatory compliance demand (EUDAMED, EU AI Act) is pulling national Regulatory Affairs pay down while the metro moves up; monitor whether this local divergence persists or whether it's an early sign of regional employers competing more aggressively for a thin regulatory bench.
Worth watching: Healthcare and manufacturing expansion locally is offsetting retail and office slowdown — track whether hospital system and manufacturing capital projects announced this fall translate into competing bids for the same quality and validation engineering talent pool Life Sci employers rely on.
Potential inflection point: Statewide WARN filings remain elevated, led by technology and agriculture sectors with life sciences largely insulated so far, but any uptick in released technical or regulatory talent entering the Tri-Cities candidate pool would be a meaningful supply signal worth tracking through November filings.
Sources
- Tri-Cities Business News — Tri-Cities unemployment rate fell to 3.5% in September 2026
- Washington Employment Security Department — Washington shed 15,400 jobs in September despite falling unemployment
- Biopharma industry labor survey — National biopharma quit rate sits at 1.9%
- EU regulatory policy tracking — EUDAMED and EU AI Act implementation driving regulatory talent demand
- Bureau of Labor Statistics — National unemployment rate at 4.2% (September 2026)
- Washington life sciences industry report — Washington life sciences job growth exceeded 50% from 2014-2024
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.